Related Experiment Video
Updated: May 3, 2026
09:33
Preparation Of Neovascular Tissues from Human Glioma Tissues for Quantitative Proteomics Analysis of Tumor Angiogenesis
Published on: March 20, 2026
120
Antiangiogenic agents for nonmalignant brain tumors
Ammar H Hawasli1, Joshua B Rubin2, David D Tran3
1Department of Neurosurgery, Washington University School of Medicine, Saint Louis, Missouri, USA.
Journal of Neurological Surgery. Part B, Skull Base
|January 18, 2014
Summary
Antiangiogenic agents like VEGF inhibitors show promise for treating vestibular schwannomas and meningiomas. These treatments were generally safe with minor side effects in a small patient group.
Area of Science:
- Oncology
- Neurology
- Pharmacology
Background:
- Vestibular schwannomas and meningiomas are primary brain tumors.
- Antiangiogenic agents target tumor vascularization.
Purpose of the Study:
- To evaluate the efficacy and safety of antiangiogenic agents, specifically vascular endothelial growth factor (VEGF) inhibitors, in patients with vestibular schwannomas and meningiomas.
- To assess treatment response and side effects in patients with neurofibromatosis type 2 (NF2) and aggressive recurrent meningiomas.
Main Methods:
- Retrospective review of 10 patients (8 male, 2 female; ages 14-70) treated with bevacizumab or pazopanib.
- Patients included those with NF2 and bilateral vestibular schwannomas/meningiomas, or aggressive recurrent meningiomas.
Main Results:
- Two patients with atypical meningioma and radiation necrosis showed dramatic partial response.
- Six NF2 patients experienced stable or slightly improved disease; two meningioma patients had progression.
- Hearing improved or remained stable in NF2 patients. Minor toxicities (epistaxis, nausea, diarrhea) were observed, with no grade 3 or 4 events.
Conclusions:
- Antiangiogenic agents demonstrate safety in treating nonmalignant brain tumors.
- These agents may be efficacious in select cases of vestibular schwannomas and meningiomas.
Keywords:
bevacizumabbrain tumormeningiomaneurofibromatosispazopanibvascular endothelial growth factorvestibular schwannomaMore Related Videos
Related Concept Videos
02:57Targeted Cancer Therapies
7.0K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.0K
01:10Mechanism of Angiogenesis
6.4K
Blood vessel formation starts early during embryonic development, around day 7. In the extraembryonic yolk sac, mesodermal precursor cells called hemangioblast proliferate and differentiate into angioblast. Angioblasts express vascular endothelial growth factor receptor 2 or VEGFR2, which binds VEGF-A, a proangiogenic factor, guiding blood vessel formation. VEGF signaling promotes angioblasts to form a blood island in the developing embryo. Angioblasts further differentiate, giving rise to...
6.4K
01:15Drugs that Stabilize Microtubules
2.2K
Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.2K